Atlas Trials

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Clinical trial NCT02718911 · COMPLETED

Trial details

NCT number
NCT02718911
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumor
Start date
2016-06-16
Primary completion
2018-12-14
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.